Cargando…

Carcinomatous meningitis in a patient with Her2/neu expressing bladder cancer following trastuzumab and chemotherapy: a case report and review of the literature

INTRODUCTION: Targeted therapies may impact the natural history of bladder cancer based upon their pharmacokinetics. The Her2/neu receptor tyrosine kinase, overexpressed by half of all primary urothelial carcinomas, has recently been examined as a therapeutic target in bladder cancer in a prospectiv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Goodman, Oscar B, Milowsky, Matthew I, Kaplan, Jodi, Hussain, Maha, Nanus, David M
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Research article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2767151/ https://www.ncbi.nlm.nih.gov/pubmed/19918289 http://dx.doi.org/10.4076/1752-1947-3-9110

Ejemplares similares

An unusual presentation of carcinomatous meningitis
por: Foo, Chuan T., et al.
Publicado: (2016)

Carcinomatous Meningitis: The Natural History of Successfully Treated Metastatic Bladder Cancer
por: Tadepalli, S., et al.
Publicado: (2011)

The Predictive Value of Serum HER2/neu for Response to Anthracycline-Based and Trastuzumab-Based Neoadjuvant Chemotherapy
por: Lee, Jung Sun, et al.
Publicado: (2012)

Carcinomatous Meningitis from Unknown Primary Carcinoma
por: Favier, L., et al.
Publicado: (2009)

Carcinomatous meningitis: Leptomeningeal metastases in solid tumors
por: Le Rhun, Emilie, et al.
Publicado: (2013)

Is there any advantage to combined trastuzumab and chemotherapy in perioperative setting her 2neu positive localized gastric adenocarcinoma?
por: Sbitti, Yassir, et al.
Publicado: (2011)

Trastuzumab for Her2/neu-positive metastatic salivary gland carcinoma: Case report and review of the literature
por: Firwana, Belal, et al.
Publicado: (2012)

Ovarian small cell carcinoma complicated by carcinomatous meningitis
por: Kira, Naoko, et al.
Publicado: (2012)

Pro1170 Ala polymorphism in HER2-neu is associated with risk of trastuzumab cardiotoxicity
por: Stanton, Sasha E, et al.
Publicado: (2015)

Regression of metastatic, radiation/chemotherapy-resistant uterine serous carcinoma overexpressing HER2/neu with trastuzumab emtansine (TDM-1)
por: Santin, Alessandro D., et al.
Publicado: (2016)

Non-small cell lung carcinoma presenting as carcinomatous meningitis
por: Paramez, A. R., et al.
Publicado: (2010)

Role of cerebrospinal fluid cytology in ‘carcinomatous meningitis’ masquerading as ‘tuberculoma’
por: Toi, Pampa Ch., et al.
Publicado: (2013)

Her2/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumab
por: Todeschini, P, et al.
Publicado: (2011)

Pathologic Complete Response of HER-2 Neu-Positive Invasive Ductal Carcinoma and Ductal Carcinoma In Situ following Neoadjuvant Chemotherapy plus Trastuzumab: A Case Report and Review of Literature
por: Gunia, Sommer R., et al.
Publicado: (2012)

Plant-Made Trastuzumab (Herceptin) Inhibits HER2/Neu+ Cell Proliferation and Retards Tumor Growth
por: Komarova, Tatiana V., et al.
Publicado: (2011)

Computational model to explore the endocrine response to trastuzumab action in HER-2/neu positive breast cancer
por: Wang, Fuzhang, et al.
Publicado: (2022)

Carcinomatous Myelitis and Meningitis after a Squamous Cell Carcinoma of the Lip
por: Pougnet, Isabelle, et al.
Publicado: (2014)

Macrophages in Giemsa-stained cerebrospinal fluid specimens predict carcinomatous meningitis
por: Kobayashi, Sayaka, et al.
Publicado: (2020)

Carcinomatous meningitis from ovarian serous carcinoma: A case report
por: Uchikura, Eijiro, et al.
Publicado: (2022)

Societal Costs and Benefits of Treatment with Trastuzumab in Patients with Early HER2neu-Overexpressing Breast Cancer in Singapore
por: de Lima Lopes, Gilberto
Publicado: (2011)

Palmitate-induced ER stress increases trastuzumab sensitivity in HER2/neu-positive breast cancer cells
por: Baumann, Jan, et al.
Publicado: (2016)

Selection of HER2/NEU negative tumor cells as a mechanism of resistance to trastuzumab in uterine serous carcinoma
por: Pelligra, Silvia, et al.
Publicado: (2020)

Carcinomatous meningitis in non-small cell lung cancer: Palliation with intrathecal treatment
por: Kumar, D. Santhosh, et al.
Publicado: (2014)

Role of EGFR and HER-2/NEU Expression in Gall Bladder Carcinoma (GBC)
por: Das, Chhanda, et al.
Publicado: (2021)

Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancer
por: Palmieri, Carlo, et al.
Publicado: (2015)

Carcinomatous meningitis: Yet another cause for rapidly progressive dementia and triphasic waves in electroencephalograph!
por: Jadav, R, et al.
Publicado: (2012)

Cerebrospinal fluid tumor markers predict treatment response in a patient with carcinomatous meningitis
por: Lin, Jiacai, et al.
Publicado: (2021)

HER2/neu overexpression in the development of muscle-invasive transitional cell carcinoma of the bladder
por: Latif, Z, et al.
Publicado: (2003)

Breast Cancer and Her-2/Neu
por: Sherwood, Roy
Publicado: (2005)

Trastuzumab Mediated T-Cell Response against HER-2/Neu Overexpressing Esophageal Adenocarcinoma Depends on Intact Antigen Processing Machinery
por: Milano, Francesca, et al.
Publicado: (2010)

Successful Treatment of HER2-neu–positive Breast Cancer With Paclitaxel and Trastuzumab Supplemented With Turkey Tail Mushrooms and Community Support
por: Smith, Julie
Publicado: (2012)

Ceritinib Treatment for Carcinomatous Meningitis with a Secondary Mutation at I1171T in Anaplastic Lymphoma Kinase
por: Ashinuma, Hironori, et al.
Publicado: (2018)

Carcinomatous meningitis as first sign of relapse in a patient with gastric Adenocarcinoma: A rare presentation
por: Mathur, Akash, et al.
Publicado: (2017)

Triphasic waves in electroencephalogram as a possible early marker of carcinomatous meningitis: a case report
por: Liu, Chang, et al.
Publicado: (2020)

Prognostic relevance of HER2/neu in acute lymphoblastic leukemia and induction of NK cell reactivity against primary ALL blasts by trastuzumab
por: Haen, Sebastian P., et al.
Publicado: (2016)

HER-2/neu diagnostics in breast cancer
por: Carney, Walter P, et al.
Publicado: (2007)

The Clinical Importance of the Heterogeneity of HER2 neu
por: Davila, Enrique, et al.
Publicado: (2010)

Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer
por: Natoli, Clara, et al.
Publicado: (2013)

History of a Carcinomatous Affection
por: Baldy, J. P.
Publicado: (1819)

Efficacy control of therapy using circulating epithelial tumor cells (CETC) as “Liquid Biopsy”: trastuzumab in HER2/neu-positive breast carcinoma
por: Pachmann, Katharina, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_7cnssrs1erbv79h1mbd5cdu6uq